Return to CG155 Overview

Psychosis and schizophrenia in children and young people: recognition and management [CG155]

Measuring the use of this guidance

Recommendation: 1.3.19

Monitor and record the following regularly and systematically throughout treatment, but especially during titration[6]: efficacy, including changes in symptoms and behaviour side effects of treatment, taking into account overlap between certain side effects and clinical features of schizophrenia (for example, the overlap between akathisia and agitation or anxiety) the emergence of movement disorders weight, weekly for the first 6 weeks, then at 12 weeks and then every 6 months (plotted on a growth chart) height every 6 months (plotted on a growth chart) waist circumference every 6 months (plotted on a percentile chart) pulse and blood pressure (plotted on a percentile chart) at 12 weeks and then every 6 months fasting blood glucose, HbA1c, blood lipid and prolactin levels at 12 weeks and then every 6 months adherence physical health. The secondary care team should maintain responsibility for monitoring physical health and the effects of antipsychotic medication in children and young people for at least the first 12 months or until their condition has stabilised. Thereafter, the responsibility for this monitoring may be transferred to primary care under shared care arrangements. [2013]

What was measured: Proportion of children and adolescents prescribed antipsychotics who have bi-annual recording of height, weight, blood pressure, pulse rate and review of side effects.
Data collection end: March 2017
100%
Area covered: UK
Source: Gnanavel Sundar, and Hussain Sharafat (2018) Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World journal of psychiatry 8(1), 27-32

What was measured: Proportion of children and adolescents prescribed antipsychotics who have annual monitoring for blood tests including liver function, renal function full blood count as well as bi-annual monitoring of serum prolactin and serum lipid profile.
Data collection end: March 2017
56%
Area covered: UK
Source: Gnanavel Sundar, and Hussain Sharafat (2018) Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World journal of psychiatry 8(1), 27-32



 Return to CG155 Overview